US 8518937
Pyrimidinediamine kinase inhibitors
granted A61KA61K31/5383A61K45/06
Quick answer
US patent 8518937 (Pyrimidinediamine kinase inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Aug 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/5383, A61K45/06, A61P, A61P35/00